Search | Clinical Trials Finder

Conditions: Congestive Heart Failure
Interventions: Ad5.hAC6, Sucrose (3%); Drug
Lead sponsor: Hammond, H. Kirk, M.D.; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 7
States / cities: San Diego, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more

Conditions: Diabetic Retinopathy
Interventions: Placebo, RG7774; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, sitagliptin, glimepiride, metformin, placebo albiglutide, placebo sitagliptin, placebo glimepiride; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,049 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 317
States / cities: Birmingham, Alabama • Dothan, Alabama • Hueytown, Alabama + 254 more

Conditions: Heart Decompensation, Acute
Interventions: BMS-986231, BMS-986231 Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Female Androgenetic Alopecia
Interventions: 5% Minoxidil, 200mg Spironolactone, 5mg Finasteride, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 60 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pain, Postoperative, Anterior Cruciate Ligament Injuries, Analgesics, Opioid
Interventions: IPACK, PLACEBO; Drug
Lead sponsor: Loyola University; Other
Eligibility: 16 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 13
States / cities: Fresno, California • Greenbrae, California • Roswell, Georgia + 10 more

Conditions: Respiratory Syncytial Virus, Human Metapneumovirus
Interventions: mRNA-1345, mRNA-1365, Placebo, Nimenrix; Biological · Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 5 Months to 24 Months
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more

Conditions: Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions: SHP639 (n=60), Placebo Comparator (n=24); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Osteomyelitis, Diabetic Foot Osteomyelitis
Interventions: Bacteriophage Therapy, Placebo; Biological · Other
Lead sponsor: Adaptive Phage Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Tuscon, Arizona • Fairfield, California • Torrance, California + 11 more

Conditions: Plaque Psoriasis
Interventions: Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Bacterial Infections
Interventions: Debio 1450, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions: Dyanavel XR, Placebo; Drug
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Melanoma
Interventions: dacarbazine plus Genasense, dacarbazine plus placebo; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Mobile, Alabama • Encinitas, California • Santa Rosa, California + 11 more

Conditions: Autism Spectrum Disorders
Interventions: Whey Protein, Rice Protein (Placebo); Dietary Supplement
Lead sponsor: Nova Southeastern University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Fort Lauderdale, Florida

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 11
States / cities: Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more

Conditions: Oxidative Stress, Muscle Strength, Resistance Training, Body Composition, Muscle Damage
Interventions: Cross Training Course, Oceanix; Other · Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Exercise Endurance
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: Lallemand Health Solutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions: DNK333, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 180 participants
Timeline: 2006 – 2007
U.S. locations: 37
States / cities: Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Diabetes Mellitus, Type 2, Hyperuricemia
Interventions: Low-fructose diet, isocaloric, Allopurinol, Placebo, Low-fructose, hypocaloric; Other · Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 40 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions: eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 77
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Chronic Heart Failure
Interventions: JTT-861 Capsules, Placebo Capsules; Drug
Lead sponsor: Akros Pharma Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more

Conditions: ALS
Interventions: Talampanel, placebo; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: San Francisco, California • Kansas City, Kansas • Baltimore, Maryland + 4 more

Conditions: Crohn's Disease
Interventions: PF-06651600 Placebo, PF-06651600, Placebo PF-06700841, PF-06700841; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 57
States / cities: Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more

Search by objective public record fields.

AC6 Gene Transfer for CHF

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

IPACK on Early Pain Scores After ACL Reconstruction

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

A Single Dose Study of Debio 1450 in Healthy Subjects

A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

The Effects of Antioxidant Supplementation on Multiple Endurance Race Performance, Physiology, and Recovery.

Impact of Probiotic Supplementation on Exercise Endurance Among Non-elite Athletes

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease